Dr. Medha Barbhaiya graduated from Columbia University where she majored in the Biological Sciences. She received her medical degree from Weill Cornell Medical College, and completed her residency in internal medicine at New York Presbyterian-Weill Cornell Medical College in 2012. During her rheumatology fellowship at Brigham and Women’s Hospital in Boston, Dr. Barbhaiya obtained a Master’s in Public Health degree from the Harvard T.H. Chan School of Public Health. In 2015, she received a Distinguished Fellow Award from the American College of Rheumatology and a Scientist Development Award from the Rheumatology Research Foundation. After completing her rheumatology fellowship, Dr. Barbhaiya joined the Brigham and Women’s Hospital faculty as a rheumatologist and clinical researcher from 2015 to 2017, during which time she was also a recipient of the Brigham and Women’s Faculty Career Development Award.
In 2017, Dr. Barbhaiya joined the Hospital for Special Surgery and Weill Cornell Medical College as a rheumatologist and clinical researcher and was also a recipient of an Investigator Award from the Rheumatology Research Foundation. Her research interests focus on studying environmental and lifestyle risk factors and outcomes related to rheumatic diseases such as systemic lupus erythematosus and antiphospholipid syndrome. Dr. Barbhaiya specializes in the treatment of systemic lupus erythematosus, antiphospholipid syndrome, inflammatory arthritis, undifferentiated connective tissue disease, pregnancy, vasculitis, scleroderma, Sjogren’s syndrome, and Raynaud’s, along with other rheumatologic conditions.
Assistant Attending Physician, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
APS Abstract Recognition Young Scholar Award, APS Foundation of America, 2016
ACR Distinguished Fellow Award, American College of Rheumatology, 2015
APS ACTION Young Scholar Award 2015
ACR REF/Abbott Medical Resident Research Award, American College of Rheumatology, 2011
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of November 13, 2019, Dr. Barbhaiya reported no relationships with healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.
MD, Weill Medical College of Cornell University, New York, NY, 2009
MPH, Harvard T.H. Chan School of Public Health, Boston, MA, 2015
NewYork-Presbyterian Hospital - Weill Cornell, New York, NY
NewYork-Presbyterian Hospital - Weill Cornell, New York, NY
Brigham and Women’s Hospital, Boston, MA, 2015
Board Certification in Rheumatology, American Board of Internal Medicine
Board Certification in Internal Medicine, American Board of Internal Medicine
Musculoskeletal Ultrasound Certification, US School of North American Rheumatologists
Barbhaiya M, Feldman CH, Guan H, Chen SK, Fischer MA, Solomon DH, Everett BM, Costenbader KH. Racial/ethnic variation in stroke rates and risks among patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2018 Jul 31.
Barbhaiya M, Tedeschi SK, Lu B, Malspeis S, Kreps David, Sparks JA, Karlson EW, Costenbader KH. Cigarette Smoking and the Risk of Systemic Lupus Erythematosus, Overall and by Anti-Double Stranded DNA Antibody Subtype, in the Nurses’ Health Study Cohorts. Ann Rheum Dis. 2018 Feb;77(2):196-202.
Barbhaiya M, Dong Y, Sparks JA, Losina E, Costenbader KH, Katz JN. Administrative Algorithms to Identify Avascular Necrosis of Bone among Patients undergoing Upper or Lower Extremity Magnetic Resonance Imaging: A validation study. BMC Musculoskeletal Disorders. 2017 Jun 19;18(1):268.
Barbhaiya M, Feldman CH, Guan H, Gomez-Puerta JA, Fischer MA, Solomon DH, Everett BM, Costenbader KH. Race/Ethnicity and Cardiovascular Events among Patients with Systemic Lupus Erythematosus. Arthritis Rheum. 2017 Sep;69(9):1823-1831.
Sparks JA*, Barbhaiya M*, Karlson EW, Ritter SY, Raychaudhuri S, Corrigan C, Lu F, Selhub J, Chasman DI, Paynter NP, Ridker PM, Solomon DH. Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial Adverse Events (CIRT-AE) Study. Semin Arthritis Rheum. Semin Arthritis Rheum. 2017 Aug;47(1):133-142.*Contributed equally
Barbhaiya M, Andrade D, Erkan D. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. Curr Rheumatol Rep. 2016 Oct; 18(10):64.
Barbhaiya M, Costenbader KH. Environmental exposures and the development of systemic lupus erythematosus. Curr Opin Rheumatol. 2016 Sep; 28(5):497-505.
Barbhaiya M, Lu B, Sparks JA, Malspeis S, Chang SC, Karlson EW, Costenbader KH. Influence of Alcohol Consumption on the Risk of Systemic Lupus Erythematosus among Women in the Nurses' Health Study Cohorts. Arthritis Care Res (Hoboken). 2017 Mar;69(3):384-392.
Barbhaiya M, Bermas BL. Evaluation and Management of Systemic Lupus Erythematosus and Rheumatoid Arthritis During Pregnancy. Clin Immunol. 2013 Nov;149(2):225-35.
Barbhaiya M, Erkan D. Top 10 clinical research developments in antiphospholipid syndrome. Curr Rheumatol Rep. 2013 Oct;15(10):367.
Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheum Reports 2011, 13(1):59-69.
Erkan D, Barbhaiya M, George D, Sammaritano L, Lockshin M. Moderate versus high-titer persistently anticardiolipin antibody positive patients: are they clinically different and does high-titer anti-beta 2-glycoprotein-I antibody positivity offer additional predictive information? Lupus 2010, 19(5):613-9.